drugset / Trial / NCT01939314

Sphenopalatine Nerve Block for Headache Tx360

NCT01939314

Phase 3 Completed 93 enrolled Indiana University
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of sphenopalatine nerve block utilizing the Tx360 (device) to deliver an anesthetic agent (bupivacaine) and to assess the duration of the analgesia.

Timeline

Start
2012-10
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 0.03 ml Intranasal

Indications